Complement Inhibitors News Today

1. In two clinical trials, iptacopan in patients with paroxysmal nocturnal hemoglobinuria (PNH) improved hemoglobin levels compared to anti-C5-treated patients and those without complement inhibitors. 2. Patients who received iptacopan generally exhibited improved secondary outcomes, including less fatigue, reduced reticulocyte and bilirubin levels, and decreased breakthrough hemolysis. Evidence Rating Level: 1 (Excellent) Study Rundown: PNH

A meta-analysis on complement inhibitors in the management of paroxysmal nocturnal hemoglobinuria (PNH) reveals an association between these interventions and positive treatment outcomes.

Rallybio Corporation , a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases,...

In Clinical Ophthalmology, a review examined the investigational therapeutics for treating dry age-related macular degeneration, including protein-based therapies.

Data at EBMT show primary endpoint met – estimated* 92.2% of complement-inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) achieving 2...

Data at EBMT show primary endpoint met - estimated* 92.2% of complement-inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) achieving 2 g/dL or more hemoglobin-level increase from baseline